133 related articles for article (PubMed ID: 17134363)
21. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.
Hunter C; Smith R; Cahill DP; Stephens P; Stevens C; Teague J; Greenman C; Edkins S; Bignell G; Davies H; O'Meara S; Parker A; Avis T; Barthorpe S; Brackenbury L; Buck G; Butler A; Clements J; Cole J; Dicks E; Forbes S; Gorton M; Gray K; Halliday K; Harrison R; Hills K; Hinton J; Jenkinson A; Jones D; Kosmidou V; Laman R; Lugg R; Menzies A; Perry J; Petty R; Raine K; Richardson D; Shepherd R; Small A; Solomon H; Tofts C; Varian J; West S; Widaa S; Yates A; Easton DF; Riggins G; Roy JE; Levine KK; Mueller W; Batchelor TT; Louis DN; Stratton MR; Futreal PA; Wooster R
Cancer Res; 2006 Apr; 66(8):3987-91. PubMed ID: 16618716
[TBL] [Abstract][Full Text] [Related]
22. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
Roos WP; Batista LF; Naumann SC; Wick W; Weller M; Menck CF; Kaina B
Oncogene; 2007 Jan; 26(2):186-97. PubMed ID: 16819506
[TBL] [Abstract][Full Text] [Related]
23. The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus.
Fujii K; Kurozumi K; Ichikawa T; Onishi M; Shimazu Y; Ishida J; Chiocca EA; Kaur B; Date I
Cancer Gene Ther; 2013 Aug; 20(8):437-44. PubMed ID: 23827879
[TBL] [Abstract][Full Text] [Related]
24. Current and future developments in the use of temozolomide for the treatment of brain tumours.
Stupp R; Gander M; Leyvraz S; Newlands E
Lancet Oncol; 2001 Sep; 2(9):552-60. PubMed ID: 11905710
[TBL] [Abstract][Full Text] [Related]
25. Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?
Siker ML; Chakravarti A; Mehta MP
Crit Rev Oncol Hematol; 2006 Nov; 60(2):99-111. PubMed ID: 17027279
[TBL] [Abstract][Full Text] [Related]
26. Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line.
Auger N; Thillet J; Wanherdrick K; Idbaih A; Legrier ME; Dutrillaux B; Sanson M; Poupon MF
Mol Cancer Ther; 2006 Sep; 5(9):2182-92. PubMed ID: 16985051
[TBL] [Abstract][Full Text] [Related]
27. Multifaceted resistance of gliomas to temozolomide.
Bocangel DB; Finkelstein S; Schold SC; Bhakat KK; Mitra S; Kokkinakis DM
Clin Cancer Res; 2002 Aug; 8(8):2725-34. PubMed ID: 12171906
[TBL] [Abstract][Full Text] [Related]
28. Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.
Kambara H; Saeki Y; Chiocca EA
Cancer Res; 2005 Dec; 65(24):11255-8. PubMed ID: 16357128
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses.
Otsuki A; Patel A; Kasai K; Suzuki M; Kurozumi K; Chiocca EA; Saeki Y
Mol Ther; 2008 Sep; 16(9):1546-55. PubMed ID: 18648350
[TBL] [Abstract][Full Text] [Related]
30. Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil.
Zemp FJ; Corredor JC; Lun X; Muruve DA; Forsyth PA
Cytokine Growth Factor Rev; 2010; 21(2-3):103-17. PubMed ID: 20483653
[TBL] [Abstract][Full Text] [Related]
31. Temozolomide: a milestone in neuro-oncology and beyond?
Mutter N; Stupp R
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1187-204. PubMed ID: 16925485
[TBL] [Abstract][Full Text] [Related]
32. Dynamic history of low-grade gliomas before and after temozolomide treatment.
Ricard D; Kaloshi G; Amiel-Benouaich A; Lejeune J; Marie Y; Mandonnet E; Kujas M; Mokhtari K; Taillibert S; Laigle-Donadey F; Carpentier AF; Omuro A; Capelle L; Duffau H; Cornu P; Guillevin R; Sanson M; Hoang-Xuan K; Delattre JY
Ann Neurol; 2007 May; 61(5):484-90. PubMed ID: 17469128
[TBL] [Abstract][Full Text] [Related]
33. Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma.
Nakashima H; Kaufmann JK; Wang PY; Nguyen T; Speranza MC; Kasai K; Okemoto K; Otsuki A; Nakano I; Fernandez S; Goins WF; Grandi P; Glorioso JC; Lawler S; Cripe TP; Chiocca EA
J Clin Invest; 2015 Nov; 125(11):4269-80. PubMed ID: 26524593
[TBL] [Abstract][Full Text] [Related]
34. Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation.
Schiff D
Cancer Invest; 2007 Dec; 25(8):776-84. PubMed ID: 17952745
[TBL] [Abstract][Full Text] [Related]
35. Oncolytic adenoviruses: design, generation, and experimental procedures.
Davydova J; Yamamoto M
Curr Protoc Hum Genet; 2013 Jul; Chapter 12():Unit 12.14. PubMed ID: 23853080
[TBL] [Abstract][Full Text] [Related]
36. MGMT methylation: a marker of response to temozolomide in low-grade gliomas.
Everhard S; Kaloshi G; Crinière E; Benouaich-Amiel A; Lejeune J; Marie Y; Sanson M; Kujas M; Mokhtari K; Hoang-Xuan K; Delattre JY; Thillet J
Ann Neurol; 2006 Dec; 60(6):740-3. PubMed ID: 17192931
[TBL] [Abstract][Full Text] [Related]
37. [Oncolytic viruses for therapy of malignant glioma].
Sosnovtceva AO; Grinenko NF; Lipatova AV; Chumakov PM; Chekhonin VP
Biomed Khim; 2016 May; 62(4):376-90. PubMed ID: 27562991
[TBL] [Abstract][Full Text] [Related]
38. Oncolytic herpes simplex virus therapy for malignant glioma: current approaches to successful clinical application.
Hua L; Wakimoto H
Expert Opin Biol Ther; 2019 Aug; 19(8):845-854. PubMed ID: 31046478
[TBL] [Abstract][Full Text] [Related]
39. [Current topics of treatment for glioma and mechanism of drug resistance].
Nagane M
Gan To Kagaku Ryoho; 2008 Jun; 35(6):918-25. PubMed ID: 18652052
[No Abstract] [Full Text] [Related]
40. Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy.
Spencer DA; Young JS; Kanojia D; Kim JW; Polster SP; Murphy JP; Lesniak MS
Ther Deliv; 2015; 6(4):453-68. PubMed ID: 25996044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
